Immunotherapy in the treatment of triple negative breast cancer

Abstract

Triple negative breast cancer (TNBC) is a very heterogeneous disease. The treatment options for most TNBC patients have so far included systemic chemotherapy, but this subtype of breast cancer soon becomes resistant to chemotherapy.

This review summarizes new immunotherapy options in combination with chemotherapy in the treatment of early and advanced triple negative breast cancer.

Keywords

• triple negative breast cancer (TNBC)
• chemotherapy
• pathological complete remission (pCR)
• PD-1/PD-L1 expression
• immunotherapy
• checkpoint inhibitors
• immune-related adverse events (irAEs)